Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) Research & Development (2024 - 2025)

Humacyte has reported Research & Development over the past 2 years, most recently at $14.6 million for Q4 2025.

  • Quarterly results put Research & Development at $14.6 million for Q4 2025, down 29.29% from a year ago — trailing twelve months through Dec 2025 was $69.3 million (down 21.78% YoY), and the annual figure for FY2025 was $69.3 million, down 21.78%.
  • Research & Development for Q4 2025 was $14.6 million at Humacyte, down from $17.3 million in the prior quarter.
  • Over the last five years, Research & Development for HUMA hit a ceiling of $23.8 million in Q2 2024 and a floor of $14.6 million in Q4 2025.